Clinical practice guideline: nosebleed (epistaxis)

DE Tunkel, S Anne, SC Payne… - … –Head and Neck …, 2020 - Wiley Online Library
Objective Nosebleed, also known as epistaxis, is a common problem that occurs at some
point in at least 60% of people in the United States. While the majority of nosebleeds are …

[HTML][HTML] Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective

A Kritharis, H Al-Samkari, DJ Kuter - Haematologica, 2018 - ncbi.nlm.nih.gov
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu
syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation …

Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia

ME Faughnan, JJ Mager, SW Hetts… - Annals of internal …, 2020 - acpjournals.org
Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

[HTML][HTML] Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report

K Benjamin, MK Vernon, DL Patrick, E Perfetto… - Value in Health, 2017 - Elsevier
Abstract Background Rare diseases (RDs) affect a small number of people within a
population. About 5000 to 8000 distinct RDs have been identified, with an estimated 6% to …

Optimal management of hereditary hemorrhagic telangiectasia

N Garg, M Khunger, A Gupta, N Kumar - Journal of Blood Medicine, 2014 - Taylor & Francis
Hereditary hemorrhagic telangiectasia (HHT), also known by the eponym Osler–Weber–
Rendu syndrome, is a group of related disorders inherited in an autosomal dominant fashion …

Diagnostic needs for rare diseases and shared prediagnostic phenomena: Results of a German-wide expert Delphi survey

S Blöß, C Klemann, AK Rother, S Mehmecke… - PloS one, 2017 - journals.plos.org
Background Worldwide approximately 7,000 rare diseases have been identified.
Accordingly, 4 million individuals live with a rare disease in Germany. The mean time to …

Pulmonary vascular complications in hereditary hemorrhagic telangiectasia and the underlying pathophysiology

S Bofarid, AE Hosman, JJ Mager, RJ Snijder… - International journal of …, 2021 - mdpi.com
In this review, we discuss the role of transforming growth factor-beta (TGF-β) in the
development of pulmonary vascular disease (PVD), both pulmonary arteriovenous …

The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study

JW Donaldson, TM McKeever, IP Hall, RB Hubbard… - Thorax, 2014 - thorax.bmj.com
Background Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant
genetic disorder of aberrant blood vessel development characterised by arteriovenous …

Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management

AM Hammill, K Wusik, RS Kasthuri - Hematology, 2021 - ashpublications.org
Hereditary hemorrhagic telangiectasia (HHT), the second most common inherited bleeding
disorder, is associated with the development of malformed blood vessels. Abnormal blood …

ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver

CD Schmid, V Olsavszky, M Reinhart, V Weyer… - Hepatology, 2023 - journals.lww.com
ALK1 controls hepatic vessel formation, angiodiversity, and... : Hepatology ALK1 controls
hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic …